Autoimmune responses to grafted lungs

Immune responses to a native collagen - Type V collagen

David S. Wilkes

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Lung transplantation is the only definitive treatment modality for many forms of end-stage lung disease. However, the lung is rejected more often than any other type of solid organ allograft due to chronic rejection known as bronchiolitis obliterans (BO). Indeed, BO is the primary reason why the 5- and 7-year survival rates are worse than any other transplanted organs. Alloimmunity to donor antigens is established as the primary mechanism that mediates rejection responses. However, newer immunosuppressive regimens designed to abrogate alloimmune activation have not improved survival. Therefore, these data suggest that other antigens, unrelated to donor transplantation antigens, are involved in rejection. Utilizing human and rodent studies of lung transplantation, our laboratory has documented that a native collagen, type V collagen (col(V)), is a target of the rejection response. Since col(V) is highly conserved, these data indicate that transplant rejection involves both alloimmune and autoimmune responses. The role of col(V) in lung transplant rejection is described in this review article.

Original languageEnglish
Pages (from-to)42-49
Number of pages8
JournalGraft
Volume6
Issue number1
DOIs
StatePublished - Jan 2003

Fingerprint

Collagen Type V
Bronchiolitis Obliterans
Lung Transplantation
Graft Rejection
Autoimmunity
Collagen
Antigens
Unrelated Donors
Lung
Histocompatibility Antigens
Immunosuppressive Agents
Lung Diseases
Allografts
Rodentia
Survival
Therapeutics

Keywords

  • Allorecognition
  • Autoimmunity
  • Lung transplantation
  • Type V collagen

ASJC Scopus subject areas

  • Transplantation

Cite this

Autoimmune responses to grafted lungs : Immune responses to a native collagen - Type V collagen. / Wilkes, David S.

In: Graft, Vol. 6, No. 1, 01.2003, p. 42-49.

Research output: Contribution to journalArticle

@article{6437bca142ec44c6bd665ea362e5fdd2,
title = "Autoimmune responses to grafted lungs: Immune responses to a native collagen - Type V collagen",
abstract = "Lung transplantation is the only definitive treatment modality for many forms of end-stage lung disease. However, the lung is rejected more often than any other type of solid organ allograft due to chronic rejection known as bronchiolitis obliterans (BO). Indeed, BO is the primary reason why the 5- and 7-year survival rates are worse than any other transplanted organs. Alloimmunity to donor antigens is established as the primary mechanism that mediates rejection responses. However, newer immunosuppressive regimens designed to abrogate alloimmune activation have not improved survival. Therefore, these data suggest that other antigens, unrelated to donor transplantation antigens, are involved in rejection. Utilizing human and rodent studies of lung transplantation, our laboratory has documented that a native collagen, type V collagen (col(V)), is a target of the rejection response. Since col(V) is highly conserved, these data indicate that transplant rejection involves both alloimmune and autoimmune responses. The role of col(V) in lung transplant rejection is described in this review article.",
keywords = "Allorecognition, Autoimmunity, Lung transplantation, Type V collagen",
author = "Wilkes, {David S.}",
year = "2003",
month = "1",
doi = "10.1177/1522162802239756",
language = "English",
volume = "6",
pages = "42--49",
journal = "Graft",
issn = "1522-1628",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Autoimmune responses to grafted lungs

T2 - Immune responses to a native collagen - Type V collagen

AU - Wilkes, David S.

PY - 2003/1

Y1 - 2003/1

N2 - Lung transplantation is the only definitive treatment modality for many forms of end-stage lung disease. However, the lung is rejected more often than any other type of solid organ allograft due to chronic rejection known as bronchiolitis obliterans (BO). Indeed, BO is the primary reason why the 5- and 7-year survival rates are worse than any other transplanted organs. Alloimmunity to donor antigens is established as the primary mechanism that mediates rejection responses. However, newer immunosuppressive regimens designed to abrogate alloimmune activation have not improved survival. Therefore, these data suggest that other antigens, unrelated to donor transplantation antigens, are involved in rejection. Utilizing human and rodent studies of lung transplantation, our laboratory has documented that a native collagen, type V collagen (col(V)), is a target of the rejection response. Since col(V) is highly conserved, these data indicate that transplant rejection involves both alloimmune and autoimmune responses. The role of col(V) in lung transplant rejection is described in this review article.

AB - Lung transplantation is the only definitive treatment modality for many forms of end-stage lung disease. However, the lung is rejected more often than any other type of solid organ allograft due to chronic rejection known as bronchiolitis obliterans (BO). Indeed, BO is the primary reason why the 5- and 7-year survival rates are worse than any other transplanted organs. Alloimmunity to donor antigens is established as the primary mechanism that mediates rejection responses. However, newer immunosuppressive regimens designed to abrogate alloimmune activation have not improved survival. Therefore, these data suggest that other antigens, unrelated to donor transplantation antigens, are involved in rejection. Utilizing human and rodent studies of lung transplantation, our laboratory has documented that a native collagen, type V collagen (col(V)), is a target of the rejection response. Since col(V) is highly conserved, these data indicate that transplant rejection involves both alloimmune and autoimmune responses. The role of col(V) in lung transplant rejection is described in this review article.

KW - Allorecognition

KW - Autoimmunity

KW - Lung transplantation

KW - Type V collagen

UR - http://www.scopus.com/inward/record.url?scp=0037275953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037275953&partnerID=8YFLogxK

U2 - 10.1177/1522162802239756

DO - 10.1177/1522162802239756

M3 - Article

VL - 6

SP - 42

EP - 49

JO - Graft

JF - Graft

SN - 1522-1628

IS - 1

ER -